{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:24:13Z","timestamp":1761863053661},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"vor","delay-in-days":731,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Vascular Surgery"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.jvs.2011.08.048","type":"journal-article","created":{"date-parts":[[2011,11,3]],"date-time":"2011-11-03T06:23:05Z","timestamp":1320301385000},"page":"400-405","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature"],"prefix":"10.1016","volume":"55","clinical-trial-number":[{"clinical-trial-number":"nct00475566","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Johannes","family":"Lammer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dierk","family":"Scheinert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Vermassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Koppensteiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus A.","family":"Hausegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman","family":"Schro\u00eb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev M.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis B.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvs.2011.08.048_bib1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1056\/NEJMra051091","article-title":"Coronary-artery stents","volume":"354","author":"Serruys","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2011.08.048_bib2","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa067193","article-title":"Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents","volume":"356","author":"Stone","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2011.08.048_bib3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1056\/NEJMoa0706258","article-title":"A comparison of bare-metal and drug-eluting stents for off-label indications","volume":"358","author":"Marroquin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2011.08.048_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ccd.20565","article-title":"Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions","volume":"67","author":"Vetrovec","year":"2006","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jvs.2011.08.048_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2008.07.005","article-title":"Systemic exposure of everolimus after stent implantation: a pharmacokinetic study","volume":"156","author":"Wiemer","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jvs.2011.08.048_bib6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jvs.2011.01.047","article-title":"First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease","volume":"54","author":"Lammer","year":"2011","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvs.2011.08.048_bib7","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa051303","article-title":"Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery","volume":"354","author":"Schillinger","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2011.08.048_bib8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1583\/05-1672.1","article-title":"Long-segment SFA stenting\u2013the dark sides: in-stent restenosis, clinical deterioration, and stent fractures","volume":"12","author":"Schlager","year":"2005","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.jvs.2011.08.048_bib9","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1161\/CIRCULATIONAHA.107.688341","article-title":"Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting","volume":"115","author":"Schillinger","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2011.08.048_bib10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/152660280701400401","article-title":"Quality of life after balloon angioplasty versus stent implantation in the superficial femoral artery: findings from a randomized controlled trial","volume":"14","author":"Sabeti","year":"2007","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.jvs.2011.08.048_bib11","first-page":"719","article-title":"Non-randomized, prospective, multi-centre evaluation of the ABSOLUTE 0.35 peripheral self-expanding stent system for occluded or stenotic superficial femoral or proximal popliteal arteries (ASSESS Trial): acute and 30-day results","volume":"48","author":"Zeller","year":"2007","journal-title":"J Cardiovasc Surg"},{"key":"10.1016\/j.jvs.2011.08.048_bib12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/00003495-200666040-00009","article-title":"Everolimus: a review of its use in renal and cardiac transplantation","volume":"66","author":"Dunn","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.jvs.2011.08.048_bib13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2011.08.048_bib14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":"Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study","volume":"80","author":"Lorber","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.jvs.2011.08.048_bib15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jvs.2011.08.048_bib16","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-09-1314","article-title":"Everolimus","volume":"16","author":"Houghton","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jvs.2011.08.048_bib17","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/00007890-199910270-00007","article-title":"A phase 1 study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-prednisone-treated renal transplants recipients","volume":"68","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.jvs.2011.08.048_bib18","first-page":"83","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jvs.2011.08.048_bib19","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1093\/ndt\/gfh322","article-title":"Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients","volume":"19","author":"Budde","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jvs.2011.08.048_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.112969","article-title":"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine","volume":"69","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jvs.2011.08.048_bib21","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/0091270005275368","article-title":"Blood concentrations of everolimus are markedly increased by ketoconazole","volume":"45","author":"Kovarik","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jvs.2011.08.048_bib22","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1161\/01.CIR.0000033973.06059.04","article-title":"Oral everolimus inhibits in-stent neointimal growth","volume":"106","author":"Farb","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2011.08.048_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.carrev.2006.05.001","article-title":"Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries","volume":"7","author":"Waksman","year":"2006","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.jvs.2011.08.048_bib24","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.299.16.1903","article-title":"Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial","volume":"299","author":"Stone","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jvs.2011.08.048_bib25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1586\/erd.09.1","article-title":"Xience V everolimus-eluting coronary stent","volume":"6","author":"Kukreja","year":"2009","journal-title":"Expert Rev Med Dev"},{"key":"10.1016\/j.jvs.2011.08.048_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1526-0968.2002.00442.x","article-title":"Membranes for therapeutic apheresis","volume":"6","author":"Nakaji","year":"2002","journal-title":"Ther Apher"},{"key":"10.1016\/j.jvs.2011.08.048_bib27","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1525-1594.1993.tb00637.x","article-title":"Dialysis treatment using an ethylene vinyl alcohol membrane and no anticoagulation for chronic uremic patients","volume":"17","author":"Cicchetti","year":"1993","journal-title":"Artif Organs"},{"key":"10.1016\/j.jvs.2011.08.048_bib28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1159\/000189101","article-title":"Evaluation of blood coagulation-fibrinolysis system in patients receiving chronic hemodialysis","volume":"73","author":"Ishii","year":"1996","journal-title":"Nephron"},{"key":"10.1016\/j.jvs.2011.08.048_bib29","first-page":"39","article-title":"Cerebral aneurysm multicenter European Onyx (CAMEO) Trial: results of a prospective observational study in 20 European centers","volume":"25","author":"Molyneux","year":"2004","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.jvs.2011.08.048_bib30","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00270-005-0148-3","article-title":"Endovascular embolization of visceral artery aneurysms with ethylene-vinyl alcohol (Onyx): a case series","volume":"29","author":"Bratby","year":"2006","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.jvs.2011.08.048_bib31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1586\/17434440.3.6.705","article-title":"A unique neuroembolic agent","volume":"3","author":"Ayad","year":"2006","journal-title":"Expert Rev Med Dev"},{"key":"10.1016\/j.jvs.2011.08.048_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.tvir.2005.10.003","article-title":"Endovascular treatment of cerebral arteriovenous malformations","volume":"8","author":"Gailloud","year":"2005","journal-title":"Tech Vasc Interventional Radiol"},{"key":"10.1016\/j.jvs.2011.08.048_bib33","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMoa035071","article-title":"Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery","volume":"349","author":"Moses","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2011.08.048_bib34","doi-asserted-by":"crossref","first-page":"89S","DOI":"10.1016\/j.jvs.2011.03.173","article-title":"Long-term effects of everolimus-eluting self-expanding stent implantation in an experimental model of peripheral vascular intervention","volume":"53","author":"Zhao","year":"2011","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvs.2011.08.048_bib35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.RVI.0000151260.74519.CA","article-title":"Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II Trial","volume":"16","author":"Duda","year":"2005","journal-title":"J Vasc Interv Radiol"},{"issue":"Suppl II","key":"10.1016\/j.jvs.2011.08.048_bib36","doi-asserted-by":"crossref","first-page":"II-30","DOI":"10.1177\/15266028060130S107","article-title":"Limitations of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popliteal arteries","volume":"13","author":"Laird","year":"2006","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.jvs.2011.08.048_bib37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2362.2007.01774.x","article-title":"Endovascular stent implantation for treatment of peripheral artery disease","volume":"37","author":"Schillinger","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jvs.2011.08.048_bib38","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1583\/05-1704.1","article-title":"Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial","volume":"13","author":"Duda","year":"2006","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.jvs.2011.08.048_bib39","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/01.CIR.0000029746.10018.36","article-title":"Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results","volume":"106","author":"Duda","year":"2002","journal-title":"Circulation"},{"issue":"Suppl 6A","key":"10.1016\/j.jvs.2011.08.048_bib40","first-page":"27E","article-title":"Paclitaxel persists in vessel wall after rapid delivery from nonpolymeric paclitaxel coating on self-expanding Nitinol stents","volume":"94","author":"Heldman","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jvs.2011.08.048_bib41","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1161\/01.CIR.0000127129.94129.6F","article-title":"Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER Clinical Trial","volume":"109","author":"Lansky","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2011.08.048_bib42","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1046\/j.1365-2125.1999.00085.x","article-title":"Entry-into-human study with the novel immunosuppressant SDZ RAD (everolimus) in stable renal transplant recipients","volume":"48","author":"Neumayer","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jvs.2011.08.048_bib43","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1586\/era.09.27","article-title":"Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma","volume":"9","author":"Oudard","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jvs.2011.08.048_bib44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1345\/aph.1M288","article-title":"Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma","volume":"45","author":"Grgic","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jvs.2011.08.048_bib45","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2011.08.048_bib46","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Journal of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521411020556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521411020556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T23:28:22Z","timestamp":1543447702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0741521411020556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0741521411020556"],"URL":"https:\/\/doi.org\/10.1016\/j.jvs.2011.08.048","relation":{},"ISSN":["0741-5214"],"issn-type":[{"value":"0741-5214","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}